Gene-Activation Firm Rana Therapeutics Closes $20.7M Series A Round | GenomeWeb

By Doug Macron

Start-up Rana Therapeutics this week announced that it has raised $20.7 million in a Series A round of financing, which the company hopes will allow it to advance a lead drug candidate into investigational new drug application-enabling studies around the end of this year.

According to Rana President and CEO Art Krieg, the 12-employee company has obtained very promising data with its core gene-activation technology in both in vitro and in vivo studies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.